OSR Holdings Inc 2024年度报告

Registrant’s telephone number, including area code:(425)635-7700 BELLEVUE LIFE SCIENCES ACQUISITION CORP.(Former name or former address, if changed since last report) Securities registered pursuant to Section12(b) of the Act: Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.Yes☐No☒ Indicate by check mark if the registrant is not required to file reports pursuant to Section13 or Section15(d) of the Act.Yes☐No☒ Indicate by check mark whether the registrant (1)has filed all reports required to be filed by Section13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),and (2)has been subject to such filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that theregistrant was required to submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectivenessof its internal control over financial reporting under Section404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registeredpublic accounting firm that prepared or issued its audit report.☐ If securities are registered pursuant to Section12(b) of the Act, indicate by check mark whether the financial statements of theregistrant included in the filing reflect the correction of an error to previously issued financial statements.☐ Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-basedcompensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to § 240.10D-1(b).☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).Yes☐No☒ The aggregate market value of the voting stock held by non-affiliates of the Registrant on June30, 2024, based upon the closing priceof $10.76 of the Registrant’s common stock as reported on the Nasdaq Stock Market, was approximately $20,295,738. Common stockheld by each officer and director and by each person known to the registrant who owned 10% or more of the outstanding voting andnon-voting common stock have been excluded in that such persons may be deemed to be affiliates. This determination of affiliatestatus is not necessarily a conclusive determination for other purposes. As of April 15, 2025, there were19,276,978shares of common stock, par value $0.0001 per share issued and outstanding. INTRODUCTORY NOTE OSR Holdings, Inc. (the “Company”) is a global healthcare company dedicated to advancing healthcare outcomes and improving thequality of life for people and their families. We aim to build and develop a robust portfolio of innovative and potentially transformativetherapies and healthcare solutions. Our current operating businesses (through our three wholly ownedsubsidiaries) include(i)developing oral immunotherapies for the treatment of cancer, (ii)developing design-augmentedbiologics for age-relatedand otherdegenerative diseases and (iii)neurovascular intervention medical device and systems distribution in Korea. the Company’s vision isto acquire and operate a portfolio of innovative health-carerelated companies globally. Prior to the closing of our initial business combination on February 14, 2025 (the “Closing”) comprising the merger via shareexchange of the Company and our target company OSR Holdings, Ltd. a corporation organized under the laws of the Republic ofKorea (“OSR”), previously reported on Form 8-K filed February 14, 2025 and further described below, the Company operated as ablank check company under the name Bellevue Life Sciences Acquisition Corp. Unless the context indicates otherwise, references in this report to “we,” “us” or the “Company” means the OSR Holdings, Inc. andour consolidated subsidiaries, and refer to the historical operations of the Company under the name of Bellevue Life SciencesAcquisition Corp. prior to the Closing (sometimes referred to herein as “BLAC”) and to the combined OSR Holdings, Inc. and itssubsidia